Clearside's SCS Microinjector Platform Highlighted in EURETINA Congress Presentations.

Clearside Biomedical will highlight its SCS Microinjector platform and CLS-AX program in multiple presentations at the 25th EURETINA Congress. The platform is designed for treating multiple retinal diseases, and the CLS-AX trial designs will be featured in a presentation by Dr. Sobha Sivaprasad. Chief Medical Officer Victor Chong will also participate in a panel discussion at the preceding Ophthalmology Futures Retina Forum.

Adagene Inc. (Nasdaq: ADAG), a biotechnology company focused on antibody-based therapy development, has announced that its Chief Strategy Officer, Mickael Chane-Du, will participate in two investor conferences in September. The events will take place in New York, New York.

The first conference, the H.C. Wainwright 27th Annual Global Investment Conference, will feature a fireside chat with Chane-Du on Monday, September 8, at 11:00 AM ET. The second event, the Morgan Stanley 23rd Annual Global Healthcare Conference, will host Chane-Du for a fireside chat on Wednesday, September 10, at 7:00 AM ET. Both conferences will provide one-on-one investor meetings and webcasts of the presentations will be available on Adagene's website for 30 days following the events [1].

Adagene Inc. is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The company leverages computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. Adagene's proprietary Dynamic Precision Library (DPL) platform includes NEObody™, SAFEbody, and POWERbody™ technologies, which enable the development of highly differentiated immunotherapy programs [2].

The company's lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). The SAFEbody platform can be applied to various antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multi-specific T-cell engagers [3].

Investors are encouraged to attend these conferences or tune in via webcast to gain insights into Adagene's innovative approach to antibody-based therapies and its promising pipeline.

References:
[1] https://www.stocktitan.net/news/ADAG/adagene-to-participate-in-two-investor-conferences-in-ci3kh19cbav7.html
[2] https://www.globenewswire.com/news-release/2025/08/26/3139243/0/en/Adagene-to-Participate-in-Two-Investor-Conferences-in-September.html
[3] https://www.marketscreener.com/news/adagene-to-participate-in-two-investor-conferences-in-september-ce7c50d9db88f620